(Q33879267)

29 July 2017

1 reference

title

Antiglaucoma medications: a review of safety and tolerability issues related to their use. (English)

1 reference

29 July 2017

J S Schuman

1

1 reference

29 July 2017

publication date

1 February 2000

1 reference

29 July 2017

published in

Clinical Therapeutics

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

167-208

1 reference

Causes of blindness in the adult population of the Republic of Ireland

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Blindness in glaucoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Number of people with glaucoma worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Glaucoma risk factors observed in the Baltimore Eye Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Genetic Risk of Primary Open-angle Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Why do some people go blind from glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Absorption of ocular timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol side effects and inadvertent overdosing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Medical Management of Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ophthalmic beta-blockers since timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Shortterm “escape” and longterm “drift.”. The dissipation effects of the beta adrenergic blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Glaucoma treatment with once-daily levobunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A multicenter evaluation of levobunolol (Vistagan) in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol treatment of chronic open-angle glaucoma and ocular hypertension. A 2.5-year multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Long-term ocular hypotensive effect of levobunolol: results of a one-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Metipranolol-associated granulomatous anterior uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Glauline (metipranolol) induced uveitis and increase in intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Bilateral anterior uveitis associated with a brand of metipranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Metipranolol-associated granulomatous iritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Possible bilateral anterior uveitis secondary to metipranolol (optipranolol) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Metipranolol-associated nongranulomatous anterior uveitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Wound healing in glaucoma filtering surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Reversal of topical antiglaucoma medication effects on the conjunctiva

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ocular surface alteration after long-term treatment with an antiglaucomatous drug

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effects of antiglaucoma drugs on ocular surface.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse reactions from timolol administration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Longterm timolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Drug-induced pemphigoid. A spectrum of diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact dermatitis due to levobunolol in eyedrops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Allergic contact dermatitis from levobunolol eyedrops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Sensitization to levobunolol eyedrops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact dermatitis from levobunolol and befunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Allergic contact dermatitis due to timolol and levobunolol in eyedrops, with no cross-sensitivity to other ophthalmic beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact dermatitis by timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Dermatitis as a side-effect of long-term topical treatment with certain beta-blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Difficulties in the interpretation of patch test reactions to ophthalmic beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Lichen planus associated with topical beta-blocker therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Psoriasis induced by ophthalmic timolol preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Nail Pigmentation following Timolol Maleate Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Tolerance to the repolarization effects of rac-sotalol during long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Systemic side effects from ophthalmic timolol and their prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Creatine phosphokinase MB band in oculopharyngeal muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol-induced bronchospasm in asthmatic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Exacerbation of obstructive airway disease by timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cardiopulmonary effects of timolol eyedrops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Syncope, bradycardia, and atrioventricular block associated with topical ophthalmic levobunolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Congestive heart failure from betaxolol. Case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The effect of timolol drops on respiratory function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Unsuspected bronchospasm in association with topical timolol--a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effect of topical timolol maleate on exercise performance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cardiovascular effects of ophthalmic timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Serum lipid physiology and the influence of glaucoma medications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical timolol decreases plasma high-density lipoprotein cholesterol level.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical timolol maleate might adversely affect serum lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical timolol and serum lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical beta blockers and serum lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical timolol and serum lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol topically and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ocular Beta-Blockers and Systemic Effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Changes in depressive status associated with topical beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse effects experienced by patients taking timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Eye drops and lethargy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Recognition of depression in geriatric ED patients by emergency physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Depression in geriatric ED patients: prevalence and recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Falls in elderly patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Severe bradycardia due to interaction of timolol eye drops and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical beta-adrenergic antagonists and quinidine. A risky interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Changing therapeutic paradigms in glaucoma management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Miotics: side effects and ways to avoid them

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A comparative study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A One-Year Multicenter Clinical Trial of Pilocarpine Gel

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Rhegmatogenous retinal detachment after initiation of ocusert therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Retinal Detachments and Topical Ocular Miotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Vitreous hemorrhage associated with pilocarpine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Impending macular hole associated with topical pilocarpine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The frequency of cataract after miotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Pilocarpine allergic contact and photocontact dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Allergic Contact Dermatitis to Echothiophate Iodide and Phenylephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Severe symptomatic atrioventricular block induced by pilocarpine eye drops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Aplastic anemia resulting from the use of carbonic anhydrase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Nonfatal methazolamide-induced aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Aplastic anemia with platelet autoantibodies in a patient after taking methazolamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Methazolamide-associated temporary leukopenia and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Acetazolamide and aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Acetazolamide-associated aplastic anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Chronic acetazolamide intoxication.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Acetazolamide delirium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Hyperkalaemia induced by carbonic anhydrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Severe acidosis from acetazolamide in a diabetic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Urine composition and stone formation during treatment with acetazolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Acetazolamide and Urolithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Urinary Calculus During Methazolamide Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Renal Failure Associated With Acetazolamide Therapy for Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Fatal reaction to acetazolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Methazolamide-induced hepatitis and pure RBC aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Taste disturbance with acetazolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Hirsutism after chronic administration of acetazolamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Transient myopia, angle-closure glaucoma, and choroidal detachment after oral acetazolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Combination of systemic acetazolamide and topical dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Irreversible corneal decompensation in patients treated with topical dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Recurrent choroidal detachment following timolol therapy in previously filtered eye. Choroidal detachment post filtering surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Hypotony and ciliochoroidal detachment following pharmacologic aqueous suppressant therapy in previously filtered patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact allergy to dorzolamide eyedrops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Nephrolithiasis with dorzolamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Prostaglandin derivates as ocular hypotensive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Prostaglandin-induced iridial pigmentation in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost and hyperpigmentation of eyelashes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Darkening of eyelashes in a patient treated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Glaucoma therapy may take your breath away

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost and cystoid macular oedema in a pseudophake

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost-associated cystoid macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

CME and anterior uveitis with latanoprost use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Anterior uveitis associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Latanoprost and herpes simplex keratitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Corneal toxicity associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Iris cyst associated with topical administration of latanoprost.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse side effects associated with latanoprost.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Systemic adverse effects associated with topically applied latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Reduction of IOP with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Topical Epinephrine in Glaucoma Suspects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Systemic hypertension in patients receiving dipivalyl adrenaline for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Clinical Comparison of Dipivalyl Epinephrine and Epinephrine in the Treatment of Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Cystoid macular edema associated with topically applied epinephrine in aphakic eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Epinephrine maculopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Epinephrine-induced cystoid macular edema in aphakic eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Correlation of Epinephrine Use and Macular Edema in Aphakic Glaucomatous Eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Allergic contact dermatitis to epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Allergic contact dermatitis and conjunctivitis from epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Follicular conjunctivitis on Dipivefrin therapy for glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact allergy to ophthalmic dipivalyl epinephrine hydrochloride: demonstration by patch testing

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Contact dermatitis from dipivefrine with possible cross-reaction to epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Pigmentation after long-term topical use of adrenaline compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Black Cornea A Complication of Topical Use of Epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

'Black cornea' after long-term epinephrine use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Nasolacrimal duct obstruction caused by topical epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Obstruction of Lacrimal Puncta Caused by Topical Epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Corneal endothelial changes with long-term topical epinephrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Increased ocular and systemic responsiveness to epinephrine in primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

An unusual systemic symptom-complex possibly related to absorption of eye-drops

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Long term effect of apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A proposed mechanism for p-aminoclonidine allergenicity based on its relative oxidative lability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

1 reference

7 January 2021

Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Eruptive dermatofibromas in AIDS patients: a form of mycobacteriosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Timolol-induced vasomotor rhinitis: a new iatrogenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

External Ocular Toxicity of Dipivalyl Epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Toxicity of Dipivalyl Epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

Corneal vascularization and opacification during long-term use of dipivefrin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988478-7

7 January 2021

10.1016/S0149-2918(00)88478-7

Identifiers

DOI

1 reference

29 July 2017

1 reference